Early predictors of liver injury in patients on parenteral nutrition.


Journal

Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592

Informations de publication

Date de publication:
10 2022
Historique:
received: 01 03 2022
revised: 29 07 2022
accepted: 06 08 2022
entrez: 2 10 2022
pubmed: 3 10 2022
medline: 5 10 2022
Statut: ppublish

Résumé

Parenteral nutrition-associated liver disease (PNALD) is diagnosed after at least 2 weeks of total parenteral nutrition (PN). However, its symptoms may occur early during PN. The aim of this study was to determine the early biochemical predictors of PNALD. This cross-sectional retrospective study included 160 patients on total parenteral nutrition. The clinical and laboratory data collected during parenteral nutrition were analyzed. Patients were assessed before the onset, on the 2nd, 7th and on the 14th day of PN according to the definition of PNALD and in search for predominant liver function tests findings. Out of 160 patients, 21 fulfilled the laboratory criteria of PNALD on the 14th day of PN. In the group of patients with PNALD, 14 met these criteria on the 7th day of PN. In multivariate logistic analyses the laboratory criteria of PNALD met on the 7th day of PN (OR = 5637; 95%Cl: 1.162-33.578; p-value = .039) were found to be of predictive value for PNALD on the 14th day. In PNALD group the 1.5-fold elevation of GGTP activity above upper limit of norm was the most prominent laboratory finding during the fourteen-day course of PN. The percentage of patients with 1.5-fold increased activity of GGTP varied in time from 76.2% to 95.2% on the 2nd and 14th day of PN, respectively. PNALD may be predicted by liver function monitoring after seven days of PN.

Sections du résumé

BACKGROUND
Parenteral nutrition-associated liver disease (PNALD) is diagnosed after at least 2 weeks of total parenteral nutrition (PN). However, its symptoms may occur early during PN. The aim of this study was to determine the early biochemical predictors of PNALD.
METHODS
This cross-sectional retrospective study included 160 patients on total parenteral nutrition. The clinical and laboratory data collected during parenteral nutrition were analyzed. Patients were assessed before the onset, on the 2nd, 7th and on the 14th day of PN according to the definition of PNALD and in search for predominant liver function tests findings.
RESULTS
Out of 160 patients, 21 fulfilled the laboratory criteria of PNALD on the 14th day of PN. In the group of patients with PNALD, 14 met these criteria on the 7th day of PN. In multivariate logistic analyses the laboratory criteria of PNALD met on the 7th day of PN (OR = 5637; 95%Cl: 1.162-33.578; p-value = .039) were found to be of predictive value for PNALD on the 14th day. In PNALD group the 1.5-fold elevation of GGTP activity above upper limit of norm was the most prominent laboratory finding during the fourteen-day course of PN. The percentage of patients with 1.5-fold increased activity of GGTP varied in time from 76.2% to 95.2% on the 2nd and 14th day of PN, respectively.
CONCLUSION
PNALD may be predicted by liver function monitoring after seven days of PN.

Identifiants

pubmed: 36184223
pii: S2405-4577(22)00436-3
doi: 10.1016/j.clnesp.2022.08.007
pii:
doi:

Substances chimiques

gamma-Glutamyltransferase EC 2.3.2.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-322

Informations de copyright

Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest All authors declare that they have no relevant or material financial interests that relate to the research described in this paper. All authors declare no conflicts of interests.

Auteurs

Marta Żalikowska-Gardocka (M)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, UCK WUM, ul. Banacha 1A, 02-097 Warsaw, Poland.

Maciej Niewada (M)

Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Poland.

Grzegorz Niewiński (G)

II Department of Anesthesiology and Intensive Care, Medical University of Warsaw, Poland Medical University of Warsaw, Poland.

Magdalena Iżycka (M)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, UCK WUM, ul. Banacha 1A, 02-097 Warsaw, Poland.

Anna Ratyńska (A)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, UCK WUM, ul. Banacha 1A, 02-097 Warsaw, Poland.

Michał Żurek (M)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, UCK WUM, ul. Banacha 1A, 02-097 Warsaw, Poland.

Agata Nawrot (A)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, UCK WUM, ul. Banacha 1A, 02-097 Warsaw, Poland.

Adam Przybyłkowski (A)

Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, UCK WUM, ul. Banacha 1A, 02-097 Warsaw, Poland. Electronic address: adam.przybylkowski@wum.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH